Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib

Cancer Research

Volumn 68, Issue 2, 2008, Pages 571-579

  Gilmer, Tona M ^a   Cable, Louann ^a   Alligood, Krystal ^a   Rusnak, David ^a   Spehar, Glenn ^a,b   Gallagher, Kathleen T ^a   Woldu, Ermias ^a   Carter, H Luke ^a   Truesdale, Anne T ^a   Shewchuk, Lisa ^a   Wood, Edgar R ^a  

^a GLAXOSMITHKLINE   (United States)

^b Adherex Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; MUTANT PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN VARIANT; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; COMPARATIVE STUDY; CRICETULUS; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HAMSTER; HUMAN; LUNG TUMOR; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN BINDING; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; GENES, ERBB-2; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MUTANT PROTEINS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 39049153060     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2404     Document Type: Article

References (51)

1. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003;7:215-34.
2. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005;23:3235-42.
3. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006;107:1207-18.
4. Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr Cancer Drug Targets 2006;6:271-94.
5. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 2005;45:357-84.
6. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8.
7. Mauro MJ, Druker BJ. STI571: a gene product-targeted therapy for leukemia. Curr Oncol Rep 2001;3:223-7.
8. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
9. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
10. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
12. Perrone F, Di Maio M, Budillon A, Normanno N. Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Curr Opin Oncol 2005;17:123-9.
13. Haber DA, Bell DW, Sordella R, et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 2005;70:419-26.
14. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-62.
15. Liu B, Bernard B, Wu JH. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins 2006;65:331-46.
16. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-9.
17. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7.
18. Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 2006;11:687-92.
19. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
20. Sawyers C. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
21. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
22. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-6.
23. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
24. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-9.
25. Hegde PS, Rusnak D, Bertiaux M, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007;6:1629-40.
26. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
27. Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small molecule tyrosin kinase inhibitor lapatinib as a first-line treatment in patients with FISH-positive advanced or metastatic breast cancer. J Clin Oncol 2005;23:3046S.
28. Petrov KG, Zhang YM, Carter M, et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg Med Chem Lett 2006;16:4686-91.
29. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4.
30. Mager P, editor. Data Analysis in Biochemistry and Biophysics. New York; Academic Press;1972.
31. Brignola PS, Lackey K, Kadwell SH, et al. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J Biol Chem 2002;277:1576-85.
32. Morrison JF. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 1969;185:269-86.
33. Copeland R. Enzymes: A practical introduction to structure, mechanism, and data analysis. NY: John Wiley and Sons;2000. p. 309.
34. Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002;297:1330-3.
35. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
36. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003;11:507-17.
37. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28.
38. Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 2002;110:763-73.
39. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002;110:775-87.
40. Shewchuk L, Hassell A, Brignola PS. ErbB4 Co-crystal. WO 2004/066921 A2;2004;200 4.
41. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-72.
42. Yun C, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27.
43. Liu Y, Shah K, Yang F, Witucki L, Shokat KM. Engineering Src family protein kinases with unnatural nucleotide specificity. Chem Biol 1998;5:91-101.
44. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001;293:876-80.
45. Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435-40.
46. Okabe T, Okamoto I, Tamura K, et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 2007;67:2046-53.
47. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-6.
48. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-71.
49. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-49.
50. Wakeling AE, Guy SP, Woodburn JR, et al. ZD 1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
51. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.